Actionable Intelligence on Pharmacodynamic Effects Improves Clinical Studies
The value of quantitative knowledge related to intra-patient heterogeneity and its advancements in clinical studies is significant. As the pharmaceutical industry continues its progression into larger, more expensive randomized Phase II studies, the risk in terms of finances, resources and time becomes much greater, especially when there is limited understanding of an asset's efficacy potential. Learn how AIQ's technology platform supports a better understanding of those assets through four life science applications.
Click to download this file